http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-H545-H

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
filingDate 1987-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1988-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1988-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-H545-H
titleOfInvention In vivo generator for radioimmunotherapy
abstract The present invention involves labeling monoclonal antibodies with intermediate half-life radionuclides which decay to much shorter half-life daughters with desirable high energy beta emissions. Since the daughter will be in equilibrium with the parent, it can exert an in-situ tumoricidal effect over a prolonged period in a localized fashion, essentially as an "in-vivo generator". This approach circumvents the inverse relationship between half-life and beta decay energy. Compartmental modeling was used to determine the relative distribution of dose from both parent and daughter nuclei in target and non-target tissues. Actual antibody biodistribution data have been used to fit realistic rate constants for a model containing tumor, blood, and non-tumor compartments. These rate constants were then used in a variety of simulations for two generator systems, Ba-128/Cs-128 (t 1/2 =2.4d/3.6m) and Pd-112/Ag-112 (t 1/2 =0.9d/192m). The results show that higher tumor/background dose ratios may be achievable by virtue of the rapid excretion of a chemically different daughter during the uptake and clearance phases. This modeling also quantitatively demonstrates the favorable impact on activity distribution of a faster monoclonal antibody tumor uptake, especially when the antibody is labeled with a radionuclide with a comparable half-life.
priorityDate 1987-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4707440-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4665897-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3663177-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6337589
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104966
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415865396
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415810487
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415861011
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6336614
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID178186
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422601322
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID177682
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID166967
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16179003
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426099772
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426099649
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415865709

Total number of triples: 28.